FOSAMAX
ALENDRONATE SODIUM
Approval overview FOSAMAX is listed in Drugs@FDA under application 020560 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ALENDRONATE SODIUM Form and strength TABLET;ORAL - EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON Submission history Latest submission status date: 2026-02-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview FOSAMAX is listed in Drugs@FDA under application 020560 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ALENDRONATE SODIUM Form and strength TABLET;ORAL - EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON Submission history Latest submission status date: 2026-02-03 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.